COVID antibody drug trial halted: hope for severe cases unfulfilled

NCT ID NCT04644185

Terminated Disease control Sponsor: Sinocelltech Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a lab-made antibody called SCTA01 in adults hospitalized with severe COVID-19. The goal was to see if it could help them recover faster. The trial was stopped early, so we don't have clear results on its effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19

Contacts and locations

Locations

SCT study site

Somers Point, New Jersey, 08244, United States
SCT study site

Buenos Aires, Argentina
SCT study site

Uberlândia, Brazil
SCT study site

Talca, Chile
SCT study site

Rionegro, Colombia
SCT study site

Monterrey, Mexico
SCT study site

Lima, Peru

More trials for these conditions

Other studies related to the condition(s) this trial covers.